A Possible Role of Galectin-9 in the Pulmonary Fibrosis of Patients with Interstitial Pneumonia

Matsumoto, Nobuhiro; Katoh, Shigeki; Yanagi, Shigehisa; Arimura, Yasuji; Tokojima, Masatoshi; Ueno, Masaki; Hirashima, Mitsuomi; Nakazato, Masamitsu

doi:10.1007/s00408-012-9446-0

Cited by 15 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously demonstrated that Gal-9 was strongly expressed in lymphocytes accumulated into the lung of patients with IP [16]. In line with previous study, Gal-9 levels significantly correlated with absolute lymphocyte Fig.…”

Section: Discussionsupporting

confidence: 90%

“…These findings suggest that Gal-9 has a role in local lung inflammation in patients with IP. Further, increased levels of Gal-9 in the lungs of IP patients may protect against pulmonary fibrosis by inhibiting the proliferation of lung fibroblasts and inducing their apoptosis [16]. In the present study, we found increased Gal-9 levels in the BALF of patients with COP, which has the best prognosis among IIPs, compared with IPF, which has the worst prognosis among IIPs.…”

Section: Discussionmentioning

confidence: 80%

“…Our previous studies demonstrated increased Gal-9 levels in the BALF of patients with CVA-IP compared with patients with IPF. Immunohistochemical investigation revealed strong Gal-9 expression in the alveolar macrophages, lymphocytes, and type II pneumocytes in patients with IP [16]. These findings suggest that Gal-9 has a role in local lung inflammation in patients with IP.…”

Section: Discussionmentioning

confidence: 83%

“…Further, we recently demonstrated increased Gal-9 expression in the lungs of patients with IP, based on immunohistochemistry [16]. The role of Gal-9 in lung fibrosis, however, remains unknown.…”

Section: Introductionmentioning

confidence: 97%

See 3 more Smart Citations

Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia

Katoh

Ikeda

Shimizu

et al. 2015

Lung

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia

Katoh

Ikeda

Shimizu

et al. 2015

Lung

Self Cite

View full text Add to dashboard Cite

show abstract

“…Human studies indicate a correlation between galectin 3 levels and ESRD, pulmonary fibrosis, heart disease and cancer 153 . Galecto Biotech is currently developing galectin-3 inhibitors for the treatment of fibrosis, specifically IPF 154 . It will be interesting to also investigate their effects on kidney disease progression.…”

Section: Targeting Fibrosismentioning

confidence: 99%

The next generation of therapeutics for chronic kidney disease

Breyer

Suszták

2016

Nat Rev Drug Discov

232

183

View full text Add to dashboard Cite

Chronic kidney disease (CKD) represents a leading cause of death in the United States. There is no cure for the disease, with current treatment strategies relying on blood pressure control through blockade of the renin angiotensin system and glycemic control. Such approaches only delay end stage kidney disease development, and can be associated with significant side effects. Recent identification of several novel mechanisms contributing to CKD development - including vascular changes, loss of podocytes and renal epithelial cells, matrix deposition, inflammation and metabolic dysregulation – has revealed new potential therapeutic approaches for CKD. This review will assess emerging strategies and agents for CKD treatment, highlighting associated challenges in their clinical development.

show abstract

The Role of Galectins in Chronic Lung Allograft Dysfunction

d’Alessandro

Bergantini

Fossi

et al. 2021

Lung

View full text Add to dashboard Cite

Background Galectins are proteins that bind β-galactosides such as N-acetyllactosamine present in N-linked and O-linked glycoproteins and that seem to be implicated in inflammatory and immune responses as well as fibrotic mechanisms. This preliminary study investigated serum galectins as clinical biomarkers in lung transplant patients with chronic lung allograft dysfunction (CLAD), phenotype bronchiolitis obliterans syndrome (BOS). Materials and Methods Nineteen lung transplant patients [median age (IQR), 55 (45–62) years; 53% males] were enrolled in the study. Peripheral blood concentrations of galectins-1, 3 and 9 were determined with commercial ELISA kits. Results Galectin-1 concentrations were higher in BOS than in stable LTX patients (p = 0.0394). In logistic regression analysis, testing BOS group as dependent variable with Gal-1 and 3 as independent variables, area under the receiver operating characteristics (AUROC) curve was 98.9% (NPV 90% and PPV 88.9%, p = 0.0003). With the stable LTX group as dependent variable and Gal-1, 3 and 9 as independent variables, AUROC was 92.6% (NPV 100% and PPV 90%, p = 0.0023). In stable patients were observed an inverse correlation of Gal-3 with DLCO% and KCO%, and between Gal-9 and KCO%. Conclusion Galectins-1, 3 and 9 are possible clinical biomarkers in lung transplant patients with diagnostic and prognostic meaning. These molecules may be directly implicated in the pathological mechanisms of BOS. The hypothesis that they could be new therapeutic targets in BOS patients is intriguing and also worth exploring.

show abstract

A Possible Role of Galectin-9 in the Pulmonary Fibrosis of Patients with Interstitial Pneumonia

Abstract: Our findings suggest that the expression level of Gal-9 in the lung is increased in patients with CVD-IP and that Gal-9 may have a protective role against pulmonary fibrosis of these patients.

Cited by 15 publications

References 35 publications

Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia

Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia

The next generation of therapeutics for chronic kidney disease

The Role of Galectins in Chronic Lung Allograft Dysfunction

Contact Info

Product

Resources

About